Labcorp Holdings Inc. has announced its third-quarter results for 2026, showcasing a solid performance that has led the company to raise its full-year guidance. The results, filed on October 28, 2026, indicate a 6.9% increase in revenue, reaching $3.81 billion compared to $3.56 billion in the same quarter last year. This growth is complemented by a 14.5% increase in adjusted earnings per share (EPS), which rose to $4.78 from $4.18.

Adam Schechter, Chairman and CEO of Labcorp, expressed confidence in the company's direction, stating, "Labcorp delivered another strong quarter with 7% revenue growth, continued margin expansion and 14.5% adjusted EPS growth, leading to a raise in our full-year guidance." He emphasized the company's commitment to innovation in specialty testing and strategic acquisitions.

Background

Labcorp Holdings Inc. (NYSE: LH) is a leader in the medical laboratory services sector, classified under the SIC code 8071, which encompasses services related to medical laboratories. The company is headquartered in Burlington, North Carolina, and is recognized for its comprehensive laboratory services and commitment to advancing healthcare through innovative testing and diagnostics.

What the Filing Says

The filing, which includes results of operations and financial condition, highlights several key metrics from the third quarter of 2026. Revenue increased to $3.81 billion, a 6.9% rise year-over-year, while diluted EPS grew to $3.22, marking a 3.3% increase. Adjusted EPS saw a more significant jump of 14.5%, reaching $4.78.

Additionally, Labcorp raised its full-year revenue growth guidance to a range of 5.9% to 6.7%, an increase of 50 basis points at the midpoint. The adjusted EPS guidance was also adjusted upward to a range of $18.30 to $18.70, reflecting an 18-cent increase at the midpoint.

Impact

This update is significant not only for Labcorp but also for the broader medical laboratory services industry. The company’s growth trajectory may influence competitors in the sector, as Labcorp continues to expand its offerings and enhance its market position. The filing indicates that Labcorp's advancements in specialty testing and strategic acquisitions are expected to be accretive to adjusted EPS in the first year and return the cost of capital by the third year.

What's Next

The filing does not specify what happens next, but Labcorp's continued focus on innovation and strategic growth initiatives is expected to drive further developments in the coming quarters. The company has already announced several acquisitions and collaborations, which may contribute to its ongoing success in the medical laboratory services industry.

For more details, the full press release can be accessed through the filing at the SEC, accession number 0000920148-26-000213.